Difficulty: Medium
Average Score: 64%
Practice
30yr NZ man goes to PNG, takes 300 mg chloroquine weekly for 2 weeks prior and 4 weeks post his trip. 3/12 later gets febrile/sweats/maleana with malaria parasites on film. The following is true
Correct answer
C
Rationale
In this scenario, option C is the correct answer: "Assume chloroquine resistance and treat accordingly." This is because the patient's presentation of febrile illness with malaria parasites despite taking chloroquine prophylaxis indicates possible resistance to chloroquine in the region he traveled to, which is common in certain areas like Papua New Guinea. Therefore, assuming chloroquine resistance and adjusting treatment is crucial to effectively manage the infection.
Option A is incorrect because the issue is not related to the dosage of chloroquine but rather the resistance of the malaria parasites to the drug. Option B suggesting the use of primaquine is also incorrect as primaquine is used for radical cure of vivax and ovale malaria, not for prevention or treatment of chloroquine-resistant falciparum malaria. Option D is partially correct in that P. falciparum is a common cause of severe malaria, but the key to addressing the situation lies in recognizing and addressing chloroquine resistance.
From an educational perspective, this question highlights the importance of understanding regional variations in malaria drug resistance patterns and the need for appropriate treatment adjustments based on local epidemiology. It underscores the significance of considering resistance patterns when selecting antimalarial agents to ensure optimal patient outcomes. This case also emphasizes the need for healthcare providers to stay updated on current guidelines and recommendations for malaria prevention and treatment.
Option A is incorrect because the issue is not related to the dosage of chloroquine but rather the resistance of the malaria parasites to the drug. Option B suggesting the use of primaquine is also incorrect as primaquine is used for radical cure of vivax and ovale malaria, not for prevention or treatment of chloroquine-resistant falciparum malaria. Option D is partially correct in that P. falciparum is a common cause of severe malaria, but the key to addressing the situation lies in recognizing and addressing chloroquine resistance.
From an educational perspective, this question highlights the importance of understanding regional variations in malaria drug resistance patterns and the need for appropriate treatment adjustments based on local epidemiology. It underscores the significance of considering resistance patterns when selecting antimalarial agents to ensure optimal patient outcomes. This case also emphasizes the need for healthcare providers to stay updated on current guidelines and recommendations for malaria prevention and treatment.